) announced updated interim data on its oncology candidate GS-9973
from an ongoing open-label, single-arm, safety and efficacy phase
II study (102). Detailed results were presented at the annual
meeting of the American Society of Clinical Oncology (ASCO).
The study is assessing the candidate, a spleen tyrosine kinase
(Syk) inhibitor, in patients suffering from relapsed or refractory
chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL:
indolent NHL, diffuse large B-cell lymphoma and mantle cell
Data from the study revealed that treatment with the candidate (as
a monotherapy) resulted in an overall response rate of 49% with a
progression-free survival rate of approximately 70% at 24 weeks in
previously treated CLL patients. Adverse events like fatigue,
dyspnea, pneumonia, nausea, atrial fibrillation and chest pain were
observed during the study.
Following the data from the study, Gilead intends to initiate new
CLL study cohorts including patients who have relapsed after being
treated with other inhibitors of the b-cell receptor (BCR) pathway.
Gilead had also presented encouraging data on its most interesting
pipeline candidate idelalisib at ASCO 2014.
A second interim analysis of a phase III study evaluating
) Rituxan for relapsed CLL showed significant improvement in
progression free survival (PFS) and overall response rate (ORR)
compared to placebo plus Rituxan, with acceptable safety.
Idelalisib is under priority review for this indication with a
response expected by Aug 6.
Gilead apart, many other companies had presented data at the ASCO.
The meeting, held in Chicago from May 30 - Jun 3, provides
companies with a platform to showcase their data to scientists,
physicians, the investment community and others.
Gilead carries a Zacks Rank #1 (Strong Buy).
) carry the same rank as Gilead in the healthcare space.
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
ROCHE HLDG LTD (RHHBY): Free Stock Analysis
ALLERGAN INC (AGN): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis
OSIRIS THERAPTC (OSIR): Free Stock Analysis
To read this article on Zacks.com click here.